Dalpiciclib was tested in the DAWNA-1 multicentric, randomized, double-blind, placebo-controlled, phase III trial in combination with fulvestrant in HR+/HER2- advanced breast cancer patients with disease progression after ET. Here, ERBB2 is linked to breast carcinoma.